Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer.

Trial Profile

Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms AXOAXI
  • Most Recent Events

    • 08 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 08 Feb 2012 Planned End Date changed from 20 Oct 2025 to 1 Dec 2025 as reported by ClinicalTrials.gov.
    • 05 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top